CellPro Inc. of Bothell, Wash., announced Wednesday the startof European clinical trials of its Ceprate SC stem cellconcentration system to demonstrate safety of stem celltherapy in conjunction with cancer treatment.
A trial being conducted at the University Hospital of Saint-Antoine in Paris includes patients with non-Hodgkin'slymphoma being treated with autologous bone marrowtransplantation. CellPro expects to expand the trial later thisyear to include several additional bone marrow transplantcenters in France.
CellPro this year completed a similar U.S. Phase I/II trial inwhich its Ceprate SC stem cell concentration system selectedstem cells from the marrow of breast cancer and lymphomapatients.
(c) 1997 American Health Consultants. All rights reserved.